Regeneron Pharmaceuticals, Inc.
Close on Nov 20, 2026Market cap $95.24BP/E 20.3Yield –
Regeneron Pharmaceuticals Indirect Research and Development Expenses by Quarter
Indirect Research and Development Expenses — Total ($M) ($M)
Regeneron Pharmaceuticals Indirect Research and Development Expenses: $724M in Q3 2026, up 7.7% from a year earlier. That is the highest of the 39 quarters on record here.
Where the Q3 2026 figure comes from
“R&D Expenses Table (FY2026Q3): Total indirect research and development expenses | 723.9 | 672.1 | 51.8 | 2,152.1 | 2,011.1 | 141.0”
Source: Form 10-Q (regn-20260930.htm, filed 2026-10-30) ↗
Reported in Form 10-Q / 10-K MD&A — Research and Development Expenses Summary Table.
quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Breakdown
What makes up indirect Research and Development Expenses
Cite this data
StockData. (2026). Regeneron Pharmaceuticals Indirect Research and Development Expenses ($M), quarterly Q1 2017–Q3 2026 [Data set]. Compiled from Regeneron Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/regn/kpis/rd-indirect-tot
See every metric in the Regeneron Pharmaceuticals KPI table. Data updated Nov 4, 2026.
See a number that looks wrong?